SCHEMBL8207649

SCHEMBL8207649

Cc1cccc(-n2cc(CNC(=O)c3nc(C(=O)NC(C)C)ccc3F)cn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.45
DDT P30046 1/20 0.41
KCNT1 Q5JUK3 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ADORA1 P30542 2/20 0.40
ADORA2A P29274 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.39
SMO Q99835 1/20 0.39
GCGR P47871 1/20 0.38
POLB P06746 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8212612 0.96 ADRB2 (0.47) ADRB2DDTKCNT1KDM4EADORA1
SCHEMBL8209034 0.88 ADRB2 (0.47) ADRB2DDTKCNT1KDM4EADORA1
SCHEMBL8211521 0.82 ADRB2 (0.57) ADRB2DDTKDM4ELMNAALDH1A1
SCHEMBL8210993 0.81 ADRB2 (0.46) ADRB2KDM4EADORA1ADORA2AALDH1A1
SCHEMBL8209103 0.80 ADRB2 (0.44) ADRB2KDM4ECYP1A2CYP2D6CYP2C19
SCHEMBL17011993 0.80 ADRB2 (0.44) ADRB2DDTKDM4EALDH1A1RAB9A
SCHEMBL17011995 0.79 ADRB2 (0.46) ADRB2DDTKDM4EALDH1A1RAB9A
SCHEMBL12853310 0.79 SUCNR1 (0.51) ADRB2DDTKDM4EALDH1A1RAB9A
SCHEMBL8192383 0.79 ADRB2 (0.40) ADRB2DDTKCNT1KDM4EALDH1A1
SCHEMBL8205629 0.78 CNR1 (0.43) ADRB2LMNACYP1A2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 ADRB2 3238/4885DDT 4423/4885KCNT1 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.